Why Pierre Fabre Pharmaceuticals’ regulatory strategy for tabelecleucel matters for rare oncology approvals
Pierre Fabre Pharmaceuticals seeks an FDA path forward for tabelecleucel in EBV-positive PTLD after a Complete Response Letter. Discover what regulators may scrutinize next.